For research use only. Not for therapeutic Use.
DRF-1042(Cat No.:I006542)is a DNA topoisomerase I inhibitor. It is being investigated as a potential treatment for solid tumors. DNA topoisomerase I is an enzyme involved in DNA replication and transcription by relieving torsional strain in DNA. Inhibition of this enzyme can disrupt DNA processes and lead to cell death, making it an attractive target for cancer therapy. DRF-1042 shows promise in preclinical studies and may have potential as a therapeutic agent for the treatment of solid tumors. Further research is ongoing to evaluate its efficacy and safety profile.
| Catalog Number | I006542 |
| CAS Number | 200619-13-2 |
| Synonyms | DRF-1042; DRF 1042; DRF1042; 5-(2′-Hydroxyethoxy)-20(S)-camptothecin.;(4S)-4-ethyl-4-hydroxy-12-(2-hydroxyethoxy)-1,12-dihydro-14H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione |
| Molecular Formula | C22H20N2O6 |
| Purity | 98% |
| Target | Antibody-drug Conjugate/ADC Related |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| Overview of Clinical Research | OriginatorDr: Reddys Laboratories<br> |
| IUPAC Name | (19S)-19-ethyl-19-hydroxy-12-(2-hydroxyethoxy)-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione |
| InChI | InChI=1S/C22H20N2O6/c1-2-22(28)15-10-17-18-13(9-12-5-3-4-6-16(12)23-18)20(29-8-7-25)24(17)19(26)14(15)11-30-21(22)27/h3-6,9-10,20,25,28H,2,7-8,11H2,1H3/t20?,22-/m0/s1 |
| InChIKey | XAKLYHGHEFMDAP-IAXKEJLGSA-N |
| SMILES | CC[C@@]1(C2=C(COC1=O)C(=O)N3C(C4=CC5=CC=CC=C5N=C4C3=C2)OCCO)O |
| Reference | <br /> |
